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1    INTRODUCTION
Atopic dermatitis is a frequent disease in humans and in dogs in industrialized
countries (LEUNG and BIEBER 2003; SUGIYAMA et al. 2007). In dogs the disease
was described for the first time in 1971 (HALLIWELL and DEBOER 2001). Today
canine atopic dermatitis (CAD) is deﬁned as a genetically predisposed, chronic
allergic disease of the skin, which is characterized by a hypersensitivity to
environmental allergens such as pollens, spores and dust (MARSELLA et al. 2009;
CHERVET et al. 2010; MEURY et al. 2011). The main symptom of CAD is intense
itching, besides licking, excoriation and biting (ROOSJE et al. 1997; GRIFFIN and
DEBOER 2001). In addition, skin lesions like erythema and papules appear on the
head, the body and the limbs (OLIVRY et al. 2002).
Cutaneous mast cells are thought to be the major effective cells in the pathogenetic
events of CAD (OLIVRY et al. 1999; MARSELLA et al. 2006). Mast cells store or
synthesize numerous inﬂammatory mediators such as eicosanoids and histamine
(BOYCE 2005). The release of these mediators results in a local or systemic
hypersensitivity reaction. Correspondingly, exocytosis of mast cell mediators is
reported to promote the clinical characteristics of CAD (GALLI and COSTA 1995;
CHURCH and LEVI-SCHAFFER 1997; MIYACHI and KUROSAWA 1998; RUKWIED
et al. 2000; WILLIAMS and GALLI 2000).
Polyunsaturated fatty acids (PUFA) of both the n-3 and n-6 families have been shown
to be incorporated into cellular membranes thereby modulating their lipid composition
(FAN et al. 2003; CHAPKIN et al. 2008; SHAIKH et al. 2009). As is known, changes
in the membrane fatty acid composition are reported to impact the membrane
physical properties as well as its organization and function (GRAMMATIKOS et al.
1994; SCHLEY et al. 2007; CHAPKIN et al. 2009; SHAIKH et al. 2009; WONG et al.
2009). Affected cellular processes are including exocytosis, trafficking, signal
transduction and molecular sorting (SIMONS and TOOMRE 2000).
The most important membrane-bound enzyme, that is involved in exocytosis and
vesicle trafficking, is phospholipase D (PLD) (SELVY et al. 2011). The translocation
and the activation of PLD intimately proceeds to the exocytosis of preformed
inflammatory mediators from mast cells that induce allergic hypersensitivity
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(COCKCROFT 2001; CHOI et al. 2002; EXTON 2002a; POWNER et al. 2002; PENG
and BEAVEN 2005). It is important to note that an alteration of the membrane lipid
composition has been reported to affect the exocytosis of preformed mediators (e.g.
histamine) and the release of newly synthesized lipid mediators (e.g. eicosanoids) by
mast cells (GUECK et al. 2003; GUECK et al. 2004a; b). The mechanism by which
the PUFA modulate mast cell exocytosis and vesicle fusion, however, is not well
understood. A possible explanation is that the modulation of the membrane
organization influences the localization and the activity of PLD.
The present mechanistic study investigates the effect of PUFA of both the n-3 and
the n-6 families on the lipid composition of membrane microdomains of C2 mast
cells. Furthermore, the impact of the modulation of the mast cell membrane lipid
composition on the localization and the activity of the PLD were studied.
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2.1 Canine atopic dermatitis (CAD)
2.1.1 Definition and etiology
CAD is a chronic, pruritic and inflammatory skin disease of dogs. The development
and severity of the disease are related to a set of interactions among genetic,
immunological, environmental, pharmacological and physiological factors as well as
to the functional state of skin barriers (GRIFFIN and DEBOER 2001; HALLIWELL
and DEBOER 2001). The term ‘food-induced allergic dermatitis’ is used to distinguish
cases in which food allergens may trigger a flare from non-food induced CAD
(OLIVRY et al. 2007; PICCO et al. 2008). CAD is caused by an immunologically
mediated reaction to allergens which in 80% of allergy-based clinical diseases is
mediated by Immunoglobulin E (IgE) (MILGROM 2002). There are two theoretical
concepts by which antigens gain access to the skin to trigger cutaneous allergic
inflammation and symptoms of the atopic dermatitis. The first hypothesis proposes
allergens to be inhaled followed by a migration of the allergens via the blood
circulation to the skin where they trigger dermal mast cells (SPERGEL et al. 1998;
CHENG et al. 2013). The second hypothesis suggests that the environmental
antigens directly reach the stratum corneum and contact the antigen-presenting cells
in the epidermis, thereby initiating cutaneous inflammation (HILL and OLIVRY 2001).
There are predisposing factors for the occurrence of CAD as breed, age, season and
disorders of the fatty acid metabolism (GRIFFIN and DEBOER 2001). Some breeds
as Labrador, Retriever, Boxer, German Shepherd, West Highland, White Terrier and
Cocker Spaniel are known to be more susceptible to CAD than others. The typical
age of onset is 6 months to 3 years . Initially the CAD seems to have a seasonal
trend (pollen season) but often gets chronic over time. Fuhrmann and coworkers
(FUHRMANN et al. 2006) reported that the deficiency of the enzymes Δ 5-desaturase
and Δ6-desaturase may also be considered as a predisposing or an aggravating
factor of CAD. Both enzymes are responsible for the synthesis of highly unsaturated
n-3 and n-6 fatty acids from α-linolenic acid (LNA) and linoleic acid (LA), which are
effective in the epidermal lipid barrier. Their dysfunction in the skin may result in a
defective epidermal lipid barrier in atopic dermatitis, thus contributing to the
pathogenesis of CAD (SCHLOTTER et al. 2009).
REVIEW OF LITERATURE
4
2.1.2 Clinical signs
Dogs with CAD exhibit characteristic clinical features (GRIFFIN and DEBOER 2001)
as pruritus (itching) which is considered a hallmark of CAD. This can occur in one or
several of these locations: around the face, ears, paws, flexor surfaces and/or the
ventrum (FAVROT et al. 2010). Generalized pruritus is also common. The primary
lesions of CAD mainly consist of diffuse, macular and papular erythema of the
affected skin . Secondary lesions as excoriations, and self-induced alopecia. Hyper-
pigmentation, scaling and lichenification are also common at pruritic sites in chronic
CAD. Moreover, atopic skin could be colonized with staphylococci and malassezia
(FAZAKERLEY et al. 2009), and therefore secondary skin and ear infections
frequently occur as further complications.
2.1.3 Diagnosis
The diagnosis of CAD is based on clinical criteria as the age (< 3 years), mostly
indoor dog, corticosteroid-sensitive pruritus, chronic or recurrent yeast infections,
affected front feet, affected ear pinnae, non-affected ear margins and non-affected
dorsolumbar area (GRIFFIN and DEBOER 2001; HILL and DEBOER 2001; FAVROT
et al. 2010). Thus, diagnosis of CAD is based on the history, the constellation of
clinical findings and the exclusion of differential diagnoses. However, none of these
criteria are exclusive to CAD (GRIFFIN and DEBOER 2001; GRIFFIN and HILLIER
2001). Other differential diagnoses must be methodically ruled out using the
intradermal skin test or allergen-specific IgE serological tests. Intradermal skin testing
has been performed for many years and is carried out by small injections of the most
common allergens into the skin (CODNER and TINKER 1995; BUCKLEY et al.
2013). More recently, measurement of allergen-specific IgE antibodies using ELISA
has become commercially available. However, since commonly false-positive
reactions are obtained with ELISA, the intradermal skin test is still considered to be
the “gold standard” for the diagnosis of CAD (FAVROT et al. 2009).
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2.1.4 Therapy
The International Task Force for CAD currently recommended a multifaceted
approach to treat dogs suffering from atopic dermatitis (OLIVRY 2011). According to
this, the treatment of CAD includes a combination of different elements including
allergen avoidance, anti-inflammatory treatments, anti-microbial treatments and
allergen-specific immunotherapy. Antibacterial or antifungal medications are helpful
when concurrent skin infections are diagnosed or when microbial allergens are
suspected to be involved in the perpetuation of CAD. Symptomatic treatment using
anti-inflammatory substances as glucocorticoids and antihistamines is important to
alleviate the inflammatory signs (GRIFFIN and DEBOER 2001; MYGIND et al. 2001).
Allergen-specific immunotherapy is considered an effective therapy for the
management of CAD. At this, an allergen extract is administered in gradually
increasing quantities to the allergic subject to ameliorate the symptoms associated
with subsequent exposure to the causative allergen (WHO definition) (BOUSQUET et
al. 1998). However, adverse effects such as pruritus, urticaria or angioedema
occasionally occur (GRIFFIN and DEBOER 2001; BILLMANN-EBERWEIN et al.
2002). These signs can be managed with antihistamines given before each allergen-
specific immunotherapy (GRIFFIN 1991). The major disadvantages of allergen-
specific immunotherapy are related to the difficulties in obtaining defined allergen
preparation and the poor quality of allergen extracts, the risk of inducing anaphylactic
side effects and the owner ̓s fear of giving injections (HILL and DEBOER 2001).
In addition to the above mentioned therapeutic approaches numerous studies have
demonstrated the effectiveness of fatty acids to reduce itching and inflammation
(HORROBIN 2000; ELIAS and FEINGOLD 2001; BILLMANN-EBERWEIN et al.
2002; ZIBOH et al. 2002; MCCUSKER and GRANT-KELS 2010). Studies utilizing
diets enriched with the PUFA as LNA, eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA), LA or gamma-linolenic acid demonstrated that
pruritius, erythema and other clinical signs of CAD are improved (BOESIGER et al.
1998; NESBITT et al. 2003; GLOS et al. 2008). In some atopic dogs,
supplementation of fatty acids alone was found to alleviate the clinical signs (SAEVIK
et al. 2004). For others a reduction in the amount of glucocorticoids required to
control pruritus was documented (GRIFFIN and DEBOER 2001; SAEVIK et al. 2004).
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PUFA were also shown to act synergistically with antihistamines (PARADIS et al.
1991; PATERSON 1995; SAEVIK et al. 2004; OLIVRY and BIZIKOVA 2013).
2.2 Mast cells
2.2.1 Life cycle and morphology
Mast cells are hematopoietic cells which playing an important role in allergy and other
type I hypersensitive responses (METCALFE et al. 1997). Mast cells arise from
pluripotential CD34+ stem cells that reside in the bone marrow and spleen
(KIRSHENBAUM et al. 1991; ARINOBU et al. 2005; GURISH and BOYCE 2006).
They are leaving the bone marrow as immature progenitors and complete their
development peripherally within connective or mucosal tissues (RODEWALD et al.
1996; BROWN et al. 2004). In vertebrates, mast cells are distributed in vascularized
tissues, in particular surfaces that are exposed to the environment, including the skin,
the respiratory and the gastrointestinal tract, where pathogens, allergens and other
environmental agents are frequently encountered (KITAMURA 1989; METCALFE et
al. 1997; KAWAKAMI and GALLI 2002; KITAMURA et al. 2006). The most important
growth factor for mast cell development is the stem cell factor that binds c-kit receptor
on the mast cell surface (COPELAND et al. 1990; SAWAI et al. 1999; GURISH and
BOYCE 2002; OKAYAMA and KAWAKAMI 2006; BISCHOFF 2007). The stem cell
factor promotes mast cell development and survival as well as adhesion to the extra
cellular matrix and has been shown to enhance the IgE-dependent mediator release
(BISCHOFF and DAHINDEN 1992). In addition, other mediators such as interleukin
(IL)-3, -4, -9, -10, nerve growth factor, some chemokines and retinoids regulate mast
cells differentiation (MARONE et al. 2002).
The diameter of mature canine mast cells ranges from 7.5 to 12 µm and the average
size of their granules is 0.47 µm, but varies according to their specific contents and
physiological status (GALLI 1990). The nucleus is oval or irregular and usually
located eccentrically (GARCIA et al. 1998). The granules are uniform in size and
appearance, and are filled with an electron-dense, homogeneous and tightly packed
material with little or no lucent halo (GARCIA et al. 1998).
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2.2.2 Mast cell function
Mast cells are well-known to be one of the first cell types of the immune system to
interact with environmental antigens and allergens, invading pathogens or
environmentally derived toxins (MYLES et al. 1995; METCALFE et al. 1997; GALLI et
al. 2005; RYAN et al. 2007). They are effector cells in the initiation of inflammatory
reactions. Activation of mast cells may be induced by 1) chemical substances, such
as toxins and venoms; 2) endogenous mediators, including tissue proteases, cationic
proteins derived from eosinophils and neutrophils; and 3) immune mechanisms that
may be IgE-dependent or IgE-independent (BENATTI et al. 2004; CHAPKIN et al.
2009). Mast cells have been shown to protect the organism against bacteria, fungi,
protozoa and perhaps even viruses (ALONSO and GARCIA-DEL PORTILLO 2004;
RADTKE and O'RIORDAN 2006; DEITSCH et al. 2009). The activation of mast cell
leads to the degranulation and release of stored mediators (e.g. histamine, tryptase
and chymase) and those produced by de-novo synthesis following stimulation (e.g.
prostaglandin D2, leukotriene C4 and thromboxane A2) (KOBAYASHI et al. 2000;
FEGER et al. 2002; GALLI et al. 2002; THEOHARIDES and KALOGEROMITROS
2006). Histamine possesses a multitude of biological activities, including the
induction of vasodilation, the enhancement of capillary permeability and the
contraction of smooth muscle cells (OHTSU et al. 2001). Tryptase and chymase
degrade various proteins of the intercellular connective tissue (e.g. collagens,
fibronectin, proteoglycans) leading to a loosening of the intercellular matrix and a
facilitated extravasation (LEES et al. 1994; GRUBER et al. 1997). Prostaglandins
modulate the vasodilatation increasing blood vessel permeability and promoting the
development of edema particularly in the presence of histamine (KALEY et al. 1985;
HATA and BREYER 2004). Leukotrienes induce leukocyte chemotaxis and an
increase in vascular permeability (TAGER et al. 2000). Thromboxanes mediate the
elevation of intracellular free Ca2+ that leads to bronchoconstriction and platelet
aggregation (SAROEA et al. 1995; JENNINGS 2009).
Mast cells are involved in the pathophysiology of allergic diseases, notably in IgE-
mediated hypersensitivity reactions of the skin, the respiratory and the
gastrointestinal tract such as atopic dermatitis, asthma, allergic rhinitis and food
allergy (BISCHOFF 2007; BROWN 2008; GALLI et al. 2008). In fact, mast cells are
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thought to be of major significance in the development of allergic reactions in CAD
via an exaggerated release of pro-inflammatory mediators (DEMORA et al. 1993;
BOESIGER et al. 1998; GRUTZKAU et al. 1998; MARSELLA and NICKLIN 2001;
BLANK and RIVERA 2004; KRAFT et al. 2004; GALLI et al. 2005). Mast cell
mediators are responsible for the complex interplay between the microvasculature
and other inflammatory cells that results in many of the clinical signs of CAD.
Histamine, for example, accounts for the continuous itching in atopic dogs
(MARSELLA and NICKLIN 2001; DAUGHERTY 2004). Tryptase, chymase,
prostaglandin E2, leukotriene C4 and thromboxane A2 are incriminated in edema,
redness and plasma extravasation (BLACK et al. 1986; JARVIKALLIO et al. 1997;
STEINHOFF et al. 2000; FUNK 2001; ALVARENGA et al. 2010).
2.2.3   The canine mast cell line C2
In the present work the canine mast cell line C2 was used. This cell line is
permanent, non-adherent and proved to have mast cell characteristics (LAZARUS et
al. 1986; DEVINNEY and GOLD 1990). The cell line was developed from
subcutaneous mast tumor cells of a dog by means of 30–50 passages in nude mice
(LAZARUS et al. 1986; DEVINNEY and GOLD 1990). The C2 cells have an average
diameter of 13 µm. Their cytoplasmic granula are average 0.47 µm in size. The IgE-
receptor-based activation of C2 cells has been shown to result in the release of
typical mast cell mediators as histamine, prostaglandin E2, prostaglandin D2,
tryptase and chymase (GUECK et al. 2003; GUECK et al. 2004a; b). All together, the
mast cell line C2 represents a reliable model to analyze mast cell reactions in vitro.
2.3 Phospholipase D (PLD)
2.3.1 PLD isoforms, structure and function
The PLD was first described by Hanahan and Chaikoff in carrot extracts (HANAHAN
and CHAIKOFF 1947; HANAHAN and CHAIKOFF 1948). In mammalian systems
PLD activity was not demonstrated until 1975, when Saito and Kanfer documented a
release of choline and ethanolamine from rat brain preparations (SAITO and
KANFER 1975). Interestingly, the enzymatic activity was found to cleave both
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phosphatidylcholine and phosphatidylethanolamine (SAITO and KANFER 1975). To
date, two isoforms of the PLD are known in mammalian tissues, namely PLD1 and
PLD2 (HAMMOND et al. 1995; COLLEY et al. 1997b), which share 55% identity
(FROHMAN et al. 1999).
The PLD enzymes have a characteristic modular structure (Figure 1) in which a
common catalytic domain is flanked by regulatory sequences. The domain structure
of PLDs contains phox homology (PX) and pleckstrin homology (PH) domains, at the
N-terminus followed by four conserved sequences (I-IV) (SUNG et al. 1999). The
catalytic sites II and III have the characteristic ‘HxKxxxxD’ motifs, abbreviated to HKD
(FROHMAN and MORRIS 1999). In addition, PLD1 has an additional 116 amino acid
‘loop’ region inserted between the II and III catalytic sites (XIE et al. 2000; LIU et al.
2001). The C-terminal 4 amino acids of mammalian PLD are evolutionarily
conserved. Modification of these residues (mutation/deletion) causes the loss of the
catalytic activity (XIE et al. 2000; LIU et al. 2001).
fs
Aoc interaction
f fff
mu me loop
oho interaction
Ck
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ff
Figure 1: Molecular structure of PLD1 and interaction sites of protein kinase C
(PKC), phosphatidylinositol-4,5-bisphosphate (PIP2), ADP-Ribosylation
Factors (ARF) and Rho GTPases.
PLD1 and PLD2 exhibit distinct differences in cellular localization. In numerous cell
lines PLD1 is localized the Golgi apparatus, the endoplasmic reticulum, perinuclear
vesicles or late endosomal vesicles (COLLEY et al. 1997a; HUGHES and PARKER
2001). Upon stimulation, PLD1 translocates to the plasma membrane (STAHELIN et
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al. 2004; LEE et al. 2005; SELVY et al. 2011). PLD2 is most often reported to be
localized at the plasma membrane, and remains there after cell stimulation (COLLEY
et al. 1997a; SARRI et al. 2003; SELVY et al. 2011).
PLD catalyzes the breakdown of the membrane phospholipid phosphatidylcholine
into phosphatidic acid and soluble choline (EXTON 1999; JONES et al. 1999).
Phosphatidic acid is a bioactive signaling molecule (EXTON 1999; JONES et al.
1999; JENKINS and FROHMAN 2005). It mediates vesicular trafficking processes
including endocytosis and exocytosis (EXTON 1999; JONES et al. 1999; JENKINS
and FROHMAN 2005). The effects of phosphatidic acid are due to the conversion to
other bioactive lipids such as lysophosphatidic acid and diacylglycerol (LISCOVITCH
et al. 2000). Lysophosphatidic acid induces the activation of multiple signaling
enzymes including phosphatidylinositol-3-kinase, extracellular signal-regulated
kinase, and phospholipase C (DIXON et al. 1999; DIXON and BRUNSKILL 1999).
Diacylglycerol is an endogenous activator of the protein kinase C (PKC)
(BERTORELLO 1992).
PLD1 has been proven to be essential for translocation of granules to the cell
periphery before their eventual fusion with the plasma membrane (BROWN et al.
1998; CHOI et al. 2002). PLD2 participates in the secretory processes as well. Due to
its location at the plasma membrane, PLD2 facilitates membrane fusion (CHOI et al.
2002; DU et al. 2004).
2.3.2 Regulation of PLD activity
Various in vitro studies have elucidated the role of certain co-factors in the
activation/inactivation of the PLD. Those mediators can be classified into 3 classes:
1) phospholipids like phosphatidylinositol-4,5-bisphosphate (PIP2); 2) small GTPases
and 3) PKC.
2.3.2.1 Phosphatidylinositol-4,5-bisphosphate (PIP2)
PIP2 is essential for the catalytic activity of both PLD1 and PLD2 (BROWN et al.
1993; BROWN and STERNWEIS 1995; HAMMOND et al. 1995; COLLEY et al.
1997b; HAMMOND et al. 1997; LOPEZ et al. 1998). The PIP2 binding site is located
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between the conserved regions II and III of the catalytic domain (Figure 1). Mutations
in this region abrogate PLD activity without altering their subcellular localization
(FROHMAN et al. 1999). Another PIP2 binding site has been reported to be present
within the PH domain. This binding site affects PLD activity by altering its subcellular
localization (OUDE WEERNINK et al. 2007).
2.3.2.2 Small GTPases
Several small GTPases as Rho and ADP-Ribosylation Factors (ARF) may activate
the PLD. The mammalian Rho-like GTPases comprise at least 10 distinct proteins:
Rho A, B, C, D, and E; Rac1 and 2; RacE; Cdc42 and TC10 (NOBES and HALL
1995; BISHOP and HALL 2000). The amino acid sequences of the Rho proteins from
various species are 50%–55% homologous to each other (VAN AELST
and D'SOUZA-SCHOREY 1997). Rho proteins, specifically RhoA, Rac1 and Cdc42
activate PLD1 through direct interaction with the C-terminus of the enzyme (EXTON
2002b; POWNER and WAKELAM 2002; OUDE WEERNINK et al. 2007). Rac2
directly activates PLD2 by binding at the C-terminus (GOMEZ-CAMBRONERO
2012).
The ARF are implicated in the regulation of both PLD1 and PLD2 (KAHN et al. 1996).
In mammals, there are six ARF isoforms (ARF 1-6) (SHOME et al. 1998; ROTH
1999). ARF stimulate PLD directly through increasing the myristoylation of a residue
at the N-terminus of the PLD (HAMMOND et al. 1997). Indirectly, ARF have been
reported to activate the phosphatidylinositol-4-phosphate-5-kinase which in turn
stimulates PLD through an activation of PIP2 (HONDA et al. 1999; JONES et al.
1999). It is documented that ARF1 stimulates PLD1 (KTISTAKIS et al. 1996), while
ARF6 stimulates PLD2 (CAUMONT et al. 1998).
2.3.2.3 Protein kinase C (PKC)
PLD1 was shown to be stimulated by the α- and β-isoenzymes of PKC in vitro,
whereas PLD2 was not affected (COLLEY et al. 1997a; EXTON 2002a; HAMMOND
et al. 1997). It has been demonstrated that the PKC interaction sites are both the N-
and C-terminal sequences of PLD1 (SINGER et al. 1995; PARK et al. 1998; MIN and
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EXTON 1998; KOOK and EXTON 2005). Furthermore, a synergistic interaction
between PKCα and other small G-proteins (RhoA and ARF1) that activate PLD1 was
observed (HAMMOND et al. 1997; THIBAULT et al. 2000; SU et al. 2006).
2.4 Fatty acids
2.4.1   Fatty acids structure
Fatty acids are hydrophobic molecules composed of a carboxylic acid group and a
chain of carbon and hydrogen atoms. Fatty acids differ structurally in four key ways:
1) the number of carbon atoms, 2) the presence and number of double bonds
between the carbon atoms, 3) the location of double bonds, and 4) the orientation of
the double bond.
An unsaturated fatty acid has one or more double bonds (Figure 2). Fatty acids with a
single double bond are termed monounsaturated fatty acids, while those with more
than one double bond are classified as polyunsaturated fatty acids (PUFA) (JUMP
2002; JUMP 2008). Fatty acids are typically divided into 4 classes based on the
length of the carbon chain: short (1-6 carbon atoms), medium (8-14 carbon atoms),
long (16–20 carbon atoms) and extra long (from 22 carbon atoms).
OH
OH
OH
O
O
O
OH
O
O
OH
αJiinolenic acid CN8WPnP
bicosapentaenoic acidI C2MWRnP
aocosahexaenoic acidI C22WSnP
iinoleic acidI CN8W2nS
Arachidonic acidI C2MW4nS
α-Linolenic acid, C18:3n3
Eicosapentaenoic acid, C20:5n3
Docosahexaenoic acid, C22:6n3
Linoleic acid, C18:2n6
Arachidonic acid, C20:4n6
Figure 2: Structures of n-3 and n-6 PUFA used in this work.
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The terms cis and trans are used to denote the relative position of the 2 carbon
substituent groups connected to a double bond. Atoms are cis if they lie on the same
side of the double bond, and they are trans if they lie on the opposite side of the
double bond. Nearly all naturally occurring unsaturated fatty acids are cis. According
to the position of the double bonds, unsaturated fatty acids are classified in several
fatty acid families: n-3, n-6, n-7 and n-9. This terminology is based on the first double
bond relative to the end of the hydrocarbon chain. For example, fatty acids
that have the first double bond at the third carbon from the terminal methyl end of the
chain are called n-3 PUFA (LÖFFLER et al. 2007).
2.4.2 Cell membranes
The traditional fluid mosaic model by Singer and Nicolson describes cell membranes
as a lipid bilayer, which is a neutral two dimensional solvent with freely diffusing
proteins (SINGER and NICOLSON 1972). Recent studies have shown that the
membrane lipids are not evenly distributed in the membrane. There are membrane
domains that are enriched in sphingolipids, cholesterol and saturated fatty acids
which are called lipid rafts (Figure 3) (PIKE 2003). Lipid rafts are structurally and
functionally distinct domains (PIKE 2003; HENDERSON et al. 2004; TRESSET 2009;
LINGWOOD and SIMONS 2010). In a keystone symposium on lipid rafts and cell
function lipid rafts were defined as “small (10-200 nm), heterogeneous, highly
dynamic, sterol- and sphingolipid-enriched domains that compartmentalize cellular
processes” (PIKE 2006). Interestingly, numerous membrane proteins are associated
with the lipid rafts (BROWN and ROSE 1992; SIMONS and IKONEN 1997; VARMA
and MAYOR 1998). Therefore, it has been proposed that the initiation and
propagation of signaling events are taking place in lipid rafts (STULNIG et al. 2001;
STULNIG 2003; SHAIKH and EDIDIN 2006).
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Figure 3: Schematic representation of a lipid raft.
2.4.3  PUFA and the immune system
PUFA have been shown to influence the immune system (HELLAND et al. 1998;
JENSEN et al. 2000; HAWKES et al. 2001; HAWKES et al. 2002; BORIS et al. 2004;
LAURITZEN et al. 2005; CALDER 2006). Beneficial effects of n-3 PUFA have been
revealed in the prevention and treatment of a variety of inflammatory and
autoimmune diseases in humans and animals, e.g. cardiovascular disease,
rheumatoid arthritis (CALDER 1998; MILES and CALDER 2012), psoriasis (MAYSER
et al. 2002), systemic lupus erythematosus (WRIGHT et al. 2008), depression
(LIPEROTI et al. 2009) or cancer (STEPHENSON et al. 2013).  EPA and DHA are
reported to inhibit the production of pro-inﬂammatory cytokines in vitro (DE
CATERINA et al. 1994; KHALFOUN et al. 1997; LO et al. 1999; BABCOCK et al.
2002; NOVAK et al. 2003; ZHAO et al. 2004) and in vivo (CALDER et al. 2006).
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PUFA are thought to modulate immune function through different mechanisms such
as: 1) modification of immune cell mediator synthesis, 2) modulation of gene
expression, 3) alteration of membrane lipid composition and membrane function
(HELLAND et al. 1998; HAWKES et al. 2001; HAWKES et al. 2002; LAURITZEN et
al. 2004; GEYEREGGER et al. 2005).
Studies have shown that the supplementation of immune cells with the n-3 PUFA as
EPA or DHA results in a partial replacement of arachidonic acid (AA) by EPA
(CALDER 2002; CALDER and GRIMBLE 2002). DHA, EPA and AA are converted to
a series of eicosanoid products through the catalytic action of cyclooxygenase (COX)
and lipoxygenase (LOX) enzymes (JUMP 2002). An increasing availability of n-3
PUFA leads to an intensified formation of the corresponding eicosanoids (BENATTI
et al. 2004; CALDER 2012). Eicosanoids from n-3 PUFA have been shown to be less
inﬂammatory and to have decreased growth promoting properties in comparison to
eicosanoids derived from n-6 PUFA (ROSE and CONNOLLY 1990; CALDER 2003;
GOTTRAND 2008). In addition, both EPA and DHA give rise to a family of lipid
mediators termed resolvins (SERHAN et al. 2000a; b; SERHAN et al. 2002; HONG et
al. 2003). E-series resolvins are produced from EPA and D-series resolvins are
originated from DHA. A large number of in vivo and in vitro studies have convincingly
shown that E- and D-series resolvins act as anti-inﬂammatory and
immunomodulatory (SERHAN et al. 2000a; b; SERHAN et al. 2002; HONG et al.
2003; MARCHESELLI et al. 2003; CALDER 2006).
Furthermore, fatty acids directly influence gene expression via the binding to cellular
receptors like peroxisome-proliferator-activated receptors (PPAR) or G-protein-
coupled receptors (GPR) (CLARKE 2004; SAMPATH and NTAMBI 2004). There are
three PPAR family members: PPARα, PPARδ and PPARγ (BORDONI et al. 2006).
PPARα activates the β-oxidation of mitochondrial and peroxisomal fatty acids in the
liver, PPARδ regulates the fatty acid oxidation in the muscle, and PPARγ enhances
fatty acid synthesis and storage (YU et al. 2003). Moreover, PPARγ is expressed in
several inflammatory cells including mast cells, monocytes, macrophages, dendritic
cells, activated T cells and B cells (TONTONOZ et al. 1998; FAVEEUW et al. 2000;
YANG et al. 2000). Synthetic ligands of PPARγ have been shown to reduce the
production of IgE-antibodies and cytokines by monocytes of patients with atopic
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dermatitis (RUHL et al. 2003). A reduction in the migration of eosinophils during the
late inflammatory phase as well as of the mast cell mediator release could be also
induced by PPARγ-ligands (SUGIYAMA et al. 2000; UEKI et al. 2004).
GPR are important signaling molecules for many aspects of cellular function.
Recently, several groups reported that five orphan receptors, designated GPR40,
GPR41, GPR43, GPR84 and GPR120, can be activated by free fatty acids. Short-
chain fatty acids are specific agonists for GPR41 and GPR43 (TAZOE et al. 2008),
while medium-chain fatty acids are agonists for GPR84 (WANG et al. 2006). Long-
chain fatty acids can activate GPR40 (ITOH et al. 2003) and GPR120 (HIRASAWA et
al. 2005). EPA and DHA exert potent anti-inflammatory effects through their
activation of GPR120. After stimulation with n-3 PUFA, GPR120 couples to β-arrestin
2, which is followed by receptor endocytosis and inhibition of transforming growth
factor-β activated kinase 1 (TAK1) activation, that results in an inhibition of both the
toll like receptor (TLR) and the TNF-α pro-inflammatory signaling pathways (OH et al.
2010).
It is well documented that the supplementation of cells with PUFA results in an
incorporation of the fatty acids into membrane phospholipids (STULNIG et al. 2001;
GREEN et al. 2007). The integrated PUFA are metabolized leading to an increase of
desaturation and elongation products of the supplemented fatty acids
(SCHMUTZLER et al. 2010; SCHUMANN and FUHRMANN 2010). The increased
proportion of unsaturated fatty acids in the cell membrane is accompanied by
increasing membrane fluidity. This increase affects the organization and dynamics of
both lipids and proteins within the membrane and can result in alterations of lipid raft
structure, which leads to modifications of cell signal transduction, receptor expression
and intercellular interaction (STULNIG et al. 2001; STILLWELL AND WASSALL
2003; GOTTRAND 2008; CHAPKIN et al. 2009). Changes in the nature and
abundance of membrane fatty acids, therefore, may alter the cells physiology and
hence the development and progression of immune cell function and the resolution of
inflammation. In fact, the incorporation of PUFA in cellular membranes has been
reported to go along with an alteration of inflammatory processes in arthritis, Crohn's
disease, dermatitis, psoriasis and ulcerative colitis (CHAPKIN et al. 2007; SIDDIQUI
et al. 2007; SIJBEN and CALDER 2007; KORADE and KENWORTHY 2008).
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2.4.4 PUFA and PLD
PUFA may influence the PLD both directly and indirectly. Directly, oleic acid, AA and
LA have been shown to have a stimulating effect on PLD2 (KIM et al. 1999). So far
there are no data on the impact of PUFA on PLD1 activity. Indirectly, the
incorporation of PUFA in membrane phospholipids is reported to result in a
reorganization of membrane microdomains (STILLWELL and WASSALL 2003;
SHAIKH and EDIDIN 2006; CORSETTO et al. 2012). Since the PLD is a membrane-
bound enzyme, such this alteration of membrane organization should impact both the
localization and the activity of the PLD.
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3 Aim of the work
It is well demonstrated that the n-3 PUFA LNA, EPA, DHA as well as the n-6 PUFA
LA prevent the release of inflammatory mediators from canine mast cells. The
mechanism of action, however, remains to be elucidated. According to the literature,
it can be speculated that PUFA supplementation modulates the lipid composition of
membrane microdomains. This might influence the localization and activity of
membrane-bound enzyme PLD which leading to an alteration of mast cell exocytosis.
Therefore, the aim of the first part of this study was to investigate the impact of a
single PUFA (LNA, EPA, DHA, LA or AA) supplementation on the lipid composition of
raft and non-raft membrane microdomains of canine C2 mast cells.
To deliver further knowledge on the effect of PUFA on the localization of the PLD, it
was necessary to transfect the canine C2 mast cells. Since this cell line is difficult to
transfect (non-adherent character), in the second part of the study, it was aimed to
establish a transfection protocol which is suitable and economic.
In the third part of the study the influence of the altered lipid composition of the mast
cell membrane on the localization and the activity of both PLD isoforms (PLD1 and
PLD2) were analyzed.
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5 DISCUSSION
Fatty acids are fundamental to life for all organisms. They serve as a source of
energy two times compared to carbohydrate or proteins. The nutritional significance
of certain PUFA became more important, when BURR and BURR reported that rats
maintained on a fat-free diet over a long period developed abnormalities
characterized by growth retardation, severe scaly dermatosis of the dorsal and pedal
skin, caudal necrosis and extensive water loss through the skin. In this deficiency
syndrome a defective barrier leading to water loss is prominent (BURR and BURR
1929). Since these deficiency symptoms, notably the cutaneous signs, could be
reversed by the dietary PUFA LA and LNA, both were designated as essential fatty
acids (SAEVIK et al. 2004; MUELLER et al. 2005).
Since then, dietary supplementation with unsaturated fatty acids, in particular DHA
and EPA have been shown to go along with a variety of health benefits. In particular,
these PUFA are reported to be of help in context of inflammatory disorders including
CAD (OLIVRY et al. 2001). It is proved in some studies that the unsaturated fatty
acids alone could alleviate clinical signs of CAD, whereas other studies postulated
that the use of PUFA spared the amount of glucocorticoids required to control
pruritus or acted synergistically with antihistamines (SAEVIK et al. 2004; OLIVRY and
BIZIKOVA 2013)). However, the underlying mechanism of action for these clinical
benefits of PUFA has not yet been elucidated in detail.
Mast cells in vitro studies may help us to enlighten the mode of action of the in vivo
influences of PUFA on CAD. In previous cell culture experiments in our lab, we
utilized physiologically relevant fatty acid doses that do not induce apoptosis.
Duration of the treatment is another important issue. Typically, we treat cell cultures
with PUFA for 1 week. Since upon supplementation, fatty acids are very rapidly
incorporated into the phospholipids of the plasma membrane, relatively little time is
required in order to observe an effect of fatty acid exposure. Additionally, removal of
PUFA supplementation has been shown to result in a rapid release of PUFA from the
plasma membrane and reversal of induced effects (SEO et al. 2006). This
demonstrates the need and constant supplementation of n-3 PUFA in order to
maintain an effect on lipid rafts.
DISCUSSION
4T
We proved that the supplementation of canine C2 mast cells with PUFA modulates
the release of histamine, the production of lipid mediators (e.g. prostaglandins) and
peptide mediators (e.g. cytokines) as well as the activity of enzymes (e.g.
tryptase) (GUECK et al. 2003, 2004a; b). At this, the n-6 PUFA AA promoted the
release of prostaglandin E2 and histamine as well as increased tryptase activity in
stimulated C2 mast cells. In contrast, supplementation of the C2 with LA, LNA, EPA
or DHA resulted in significantly decreased levels of prostaglandin E2, histamine and
tryptase (GUECK et al. 2003, 2004a; b). Furthermore, it has been proven that EPA
enrichment of C2 cells decreased the activity of cPLA2 and increased the activity of
PPARγ, in contrary to AA (GUECK et al. 2007). In addition, exposure of cells to LNA,
EPA, LA or AA has been shown to induce significant increase in the production of
reactive oxygen species and lipid peroxides which resulted in cellular apoptosis. The
differences between the PUFA tested is directly proportional to the unsaturation
degree of fatty acids as well as the position of double bonds (SCHMUTZLER et al.
2010). These results are in accordance with in vivo studies which proved the
biological relevance of LNA, EPA, DHA and LA in the rendering of pruritus and other
signs in atopic dogs (MEINERI et al. 2012; GLOS et al. 2008; SCOTT et al. 1997).
The mechanism by which dietary fatty acids influence the exocytosis process of mast
cells, however, remains to be elucidated. It has been suggested that the
supplementation of cells with PUFA modifies membrane lipid composition which in
turn is thought to affect the organization of membrane enzymes such as the PLD.
Notably, PLD contributes to exocytosis regulation and vesicle trafficking (SELVY et
al. 2011). Accordingly, in the present work light is shed on the effects of a PUFA
supplementation of mast cells on the lipid profile of membrane microdomains.
Furthermore, emphasis is put on the impact of a modified membrane lipid
environment on the cellular trafficking and activity of the PLD.
5.1 Detergent-free isolation of lipid rafts
To assess the influence of n-3 and n-6 PUFA on the fatty acid composition of
membrane microdomains of C2 mast cells, a lipid raft isolation was performed.
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So far, two methodologies are described for isolation of rafts: detergent-based and
detergent-free. Traditional lipid raft preparation is carried out by homogenizing cells in
cold buffer containing 1% Triton X-100 followed by flotation in a linear 5% to 30%
sucrose gradient (BROWN and ROSE 1992). However, the product turned out to be
fairly inconsistent depending on physical manipulations (ROPER et al. 2000). The
procedure yielded unfavorable interactions between Triton X-100, cholesterol and
sphingomyelin (MAYOR and MAXFIELD 1995; BROWN 1998). A variety of
detergents other than Triton X-100 have been used to isolate lipid rafts so far,
including Lubrol WX, Lubrol PX, Brij 58, Brij 96, Brij 98, Nonidet P40, CHAPS and
octylglucoside (ILANGUMARAN et al. 1999; MADORE et al. 1999; ROPER et al.
2000; DREVOT et al. 2002; SCHUCK et al. 2003; SLIMANE et al. 2003). However,
significant differences in lipid and protein content have been observed among them
(ILANGUMARAN et al. 1999; ROPER et al. 2000; DREVOT et al. 2002). Moreover,
lipids and proteins yielded from these preparations did not represent raft
characteristics of intact cells (MAYOR and MAXFIELD 1995; BROWN 1998). To
overcome these drawbacks detergent-free purification techniques have been
developed. Macdonald and Pike (MACDONALD and PIKE 2005) introduced a
detergent-free flotation method. This method appears to yield highly purified
membranes domains, which seem to represent the characteristics of lipid rafts in
intact cells (MACDONALD and PIKE 2005; PERSAUD-SAWIN et al. 2009).
Macdonald and Pike established their protocol using Chinese hamster ovary and
Hela cells. In a previous work in our lab, this protocol was adapted for the
macrophage cell line RAW 264.7 (SCHUMANN et al. 2011). In the present work the
application area was broaden further for the mast cell line C2. Thereby, a clear
separation of lipid rafts from non-rafts was achieved. Remarkably, it is the first time
that lipid rafts were isolated from mast cells using a detergent-free procedure. The
contents of cholesterol and protein in lipid rafts as well as non-raft membranes were
not affected by the fatty acid supplied (data not shown). This is in accordance with
recent data on RAW264.7 macrophages of our group and suggests that, at least in
our system, the modulation of the membrane domains occurs without reduction in
cholesterol. Others found, that DHA, influence cholesterol content of lipid rafts, more
than EPA (CORSETTO et al. 2012). A number of experiments demonstrated the
…….
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incompatibility between cholesterol and DHA. Studies using a variety of techniques
indicate that the poor affinity of DHA for cholesterol provides a lipid-driven
mechanism for lateral phase separation of cholesterol-rich lipid microdomains from
the surrounding membrane.
On the contrary, AA increases cholesterol together with a slight increase of
sphingomyelin. AA represents a major PUFA in lipid rafts which is in agreement with
Pike and his collaborators (PIKE et al. 2002). It is mainly linked to
phosphatidylethanolamine that is enriched in the inner membrane leaflet, while
cholesterol and sphingomyelin are mainly in the outer leaflet.
Thus, the chemical-physical features of fatty acids and related phospholipids are
mainly influenced by their length and double bounds. Little variations may greatly
influence their ability to interact in membranes with other lipids such as cholesterol.
The different effects of EPA, DHA and AA integrated in raft lipids may be explained
by their structural differences. Summing up, this method allows the isolation of
concentrated and highly purified lipid rafts, which enable us to study the changes in
the lipid composition of rafts due to PUFA supplementation in mast cells. It is the
technique of choice for the physical and chemical characterization of lipid rafts, thus
contributing to the understanding of the role of the membrane microdomains in cell
signaling and transport processes.
5.2 Fatty acid composition in rafts and non-raft membranes of C2 mast cells
as modulated by PUFA supplementation
It is well documented that the organization of lipid rafts modulates many biological
processes of cells (SILVEIRA E SOUZA et al. 2011). Therefore, in the present work
the effect of a PUFA supplementation on the lipid composition of membrane
microdomains of C2 was assessed. Supplementation of C2 with n-3 PUFA (LNA,
EPA or DHA) or n-6 PUFA (LA or AA) resulted in an increase in the content of the
supplemented fatty acids in both raft and non-raft membrane domains. A rise of the
desaturation and elongation products of the supplemented fatty acid was found as
well. It is worth to mention that the PUFA enrichment was accompanied by an
increase of the Methylene Bridge Index in both rafts and non-rafts, which indicates a
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higher unsaturation status of the cell membrane (BASIOUNI et al. 2012a).
Membranes with an increased unsaturation are reported to be altered in their
physical properties including permeability, elasticity, fluidity, vesicle formation, lateral
lipid segregation and flip-flop mechanisms (HUSTER et al. 1999; ARMSTRONG et al.
2003; STILLWELL and WASSALL et al. 2003; YANG et al. 2011). The molecular
order of the membrane microdomains is disrupted, which leads to a displacement of
acylated proteins out of or into lipid rafts. As a result we and others (CORSETTO et
al. 2012; SHAIKH 2012) assume an alteration in cellular functions and signal
transduction.
A significant part of the literature describing the effects of PUFA on lipid rafts utilizes
either fish oil, or EPA and DHA in combination (SCHLEY et al. 2007). However,
whether the effects of n-3 PUFA supplementation on lipid raft perturbation are due to
EPA, DHA, or the combination, is uncertain. EPA is shorter and less unsaturated
than DHA, suggesting that it may not be as efficient as DHA perturbing lipid rafts. It
remains to be determined whether the structural differences of these two fatty acids
results in functional differences with regard to lipid raft perturbation. Based on the
current literature, it is clearly evident that DHA has a significant effect on lipid raft
organization (TURK and CHAPKIN 2013). The effect of EPA on lipid rafts is less well
documented. Additionally, there are data indicating that DHA uniquely modifies the
lateral organization of lipid raft proteins (SHAIKH 2012). These studies suggest a
specificity of DHA in disrupting lipid rafts.
5.3 Establishment of a transfection protocol for the suspension mast cell
line C2
In the next step it was intended to test whether the membrane-bound PLD are
affected by the PUFA-induced reorganization of the lipid rafts.
To visualize the intracellular localization of PLD in C2 mast cells and to study the
influence of PUFA on PLD distribution, mast cells were transfected with GFP-fusion
plasmids encoding PLD1 or PLD2. It is important to note that the mast cell line used
for the experiments is a suspension cell line. This type of cells has traditionally
proven to be very difficult to transfect. Electroporation is reported to result in a low
......
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transfection efficiency and a high cell mortality (GEHL 2003, GRESCH et al. 2004).
Liposome-based transfection methods significantly reduce the risk of cell death but
are limited in transfection efficiency as well (LANDAUER et al. 2002; MONTIER et al.
2004; PRAVEEN et al. 2011). The limited transfection efficiency of C2 may be due to
the non-adherent character of the cells, which minimizes the possibility of the DNA-
polymer complex to come into closer contact with the cell membrane, thus
decreasing the delivery of nucleic acid into the cells. Hence, overcoming the non-
adherent character of the cells might improve transfection efficiency.
To that end cell culture plates were coated using different materials which are
reported to support cell adhesion. The most frequently utilized extracellular matrices
used so far are poly-L-lysine and collagen (ZHANG et al. 2012). However, poly-L-
lysine is proved to activate mast cells via a distinct Fc3RI-independent pathway
ultimately leading to degranulation (DENG et al. 2009). Therefore, poly-L-lysine was
not convenient for the present study. Collagen as coating material has not reported
as mast cell activator, so far. Indeed in the present work, basic mast cell functions,
e.g. histamine release or β-hexosaminidase activity, were found not to be changed
by collagen coating. However, the collagen coating strategy resulted in an
unsatisfying transfection efficiency. Therefore, it was important to find another coating
material that enables higher transfection efficiency. Avian egg white is reported as a
natural “inert” material, which may promote the adhesion ability of suspension cells
(LEBARON and ATHANASIOU 2000; KAIPPARETTU et al. 2008). Moreover, egg
white is transparent, that allows easy monitoring of cells growth. It is also inexpensive
and easily available. Using chicken egg white, there were no remarkable changes in
the morphological features of the cells. The cellular functions of mast cells were also
not altered. The liberation of inflammatory mediators such as histamine and β-
hexosaminidase were not changed in cells cultured in egg white-coated plates in
comparison to uncoated plates. In addition, coating with egg white improved the
transfection efficiency to 50% versus 5% in case of uncoated cells. Moreover, this
protocol has additional advantages as it is economic, time-saving and very simple.
Summing up, coating of cell culture plates with egg white as presented in this work
could solve the crucial problem related to the transfection of suspension cell lines
(BASIOUNI et al. 2012b).
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5.4 Influence of PUFA on the distribution of PLD isoforms with regard to
stimulation status
Using the new transfection protocol the impact of a PUFA supplementation of mast
cells on the localization as well as the stimulation-induced translocation of the PLD
was identified. In unsupplemented cells, PLD2 was localized at the plasma
membrane. Stimulation of the cells had no influence on PLD2 localization. PLD1, in
contrast, was found to be localized within intracellular vesicular structures including
Golgi apparatus, lysosomal and endosomal vesicles of unstimulated C2 mast cells.
After stimulation, PLD1 shifted to the plasma membrane. These results are in
agreement with previous studies on various mast cell lines (BROWN et al. 1998;
COCKCROFT 2001; CHOI et al. 2002; DU et al. 2003; SARRI et al. 2003; DU et al.
2004; HUANG et al. 2005; GEMEINHARDT et al 2009; DISSE et al 2009; OLIVEIRA
and DI PAOLO 2010).
PUFA supplementation did not affect the localization of PLD2. On the other hand, for
PLD1 an effect of LA, LNA, EPA and DHA on the stimulation-induced translocation
was found. The n-6 PUFA LA as well as the n-3 PUFA LNA, EPA and DHA
prevented the migration of the PLD1 to the plasma membrane. The n-6 PUFA AA did
not affect PLD1 translocation.
DHA and EPA are reported to abolish a stimulation-induced increase of intracellular
Ca2+ (PIGNIER and LE GRAND 2008; VANHORN et al. 2012), which in turn
suppresses the stimulation-mediated translocalization of PKCα (NAIR et al. 2001;
DENYS et al. 2005). PKCα and PLD1 are translocated together (MOCHLY-ROSEN
et al 1990; GARBI et al 2000; HU and EXTON 2003). Thus, it is possible, that the
inhibition of PKCα translocation by EPA and DHA is accompanied by an inhibition of
PLD1 translocation. On the opposite, AA has been described to promote the
stimulation-induced increase of intracellular Ca2+ (FIORIO PLA and MUNARON
2001; SERGEEVA et al. 2003) and to be a direct activator of PKCα in vitro (KHAN et
al. 1995; LOPEZ-NICOLAS et al. 2006). As a consequence, PLD1 migrated to the
plasma membrane in AA-supplemented cells upon stimulation. So far, the impact of
LA and LNA on PKCα has not been determined. However, the mechanism of
inhibition of PLD1 translocation by LA and LNA could be the same as for EPA and
DHA.
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It is well documented, that PLD1 plays an essential role in mast cell degranulation
(SELVY et al. 2011). The enzyme is involved in transport and fusion of the secretory
granules to the plasma membrane and subsequently enhances the release of
preformed inflammatory mediators by mast cells (DINH and KENNERLY 1991; WAY
et al. 2000). The inhibition of the translocation of PLD1 to the plasma membrane by
LA, LNA, EPA and DHA could be an explanation for the arresting effect of these
PUFA on the stimulation-induced release of the pro-inflammatory mediators from C2
mast cells observed by Gueck and co-workers. Likewise, the observation that AA
does not prevent PLD1 translocation to the plasma membrane goes along with the
fact that supplementation of mast cells with AA has no inhibitory effect on mast cell
mediator release (GUECK et al. 2003; GUECK et al. 2004a; b).
5.5 Influence of PUFA supplementation on total PLD activity
In the next step the impact of a PUFA supplementation on the total PLD activity was
measured.
In unstimulated C2 mast cells, total PLD exhibited low basal activity regardless
whether and which PUFA was supplemented. Stimulation of the mast cells with
mastoparan significantly increased total PLD activity. This result is in accordance with
previous studies (MIZUNO et al. 1995; LEE et al. 1998; MUNNIK et al. 1998;
GEMEINHARDT et al. 2009). Enrichment of the C2 mast cells with PUFA further
enhanced the total PLD activity of the cells. These findings are in compliance with
earlier studies on COS-1 cells (GEMEINHARDT et al. 2009) and human peripheral
blood mononuclear cells (BECHOUA et al. 1998; DIAZ et al. 2002), which also report
that PUFA boost the stimulation-induced total PLD activity. Indeed, for the first time
the data in the present study highlight that PUFA enhance the total PLD activity in
mast cells (BASIOUNI et al. 2013).
5.6 Influence of PUFA supplementation on the activity of PLD isoforms
To ascertain, which of the two PLD isoforms is implicated in the PUFA-mediated
increase of total PLD activity, the activity was measured in the presence of the
specific PLD1 and PLD2 inhibitors VU0155069 (LAVIERI et al. 2010) and
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VU0364739-HCl (SCOTT et al. 2009), respectively. The inhibitors have been
described as highly potent and selective. However, since they have not been used in
C2 mast cells so far, a dose-response curve for each inhibitor was determined. The
recommended dose, according to the manufacturer, of either PLD1 or PLD2
inhibitors resulted in a 60 % decrease of PLD1 or PLD2 activity in C2 mast cells. This
inhibitory level offered a possibility to study the impact of PUFA on PLD isoform
activity.
Using either PLD2 or PLD1 inhibitor resulted in a significant drop in the PLD activity
of stimulated but unsupplemented C2 mast cells. DHA supplementation did not
influence the decrease in the PLD activity induced by the PLD2 inhibitor, but
abolished the inhibitory action of the PLD1 inhibitor. AA supplementation abolished
the inhibitory effects of both the PLD2 and the PLD1 inhibitor.
There are common activators for both PLD1 and PLD2, namely ARF and PIP2
(SELVY et al. 2011), moreover, there are also isoform-specific PLD regulatory
proteins. PLD1 is exclusively activated by the GTPases Rho, Rac1 and Cdc42 as
well as the PKCα (SELVY et al. 2011). PLD2 is selectively triggered by the GTPase
Rac2 as well as the Src kinase (SELVY et al. 2011).
DHA has a divergent effect on PLD1 activating mediators, since it activates ARF
(DIAZ et al. 2002) but inhibits Rho and PKCα activity (YOUNG et al. 2000; YI et al.
2007). These divergent influences of DHA on PLD1-activating mediators presumably
neutralize each other thus resulting in a diminishing effect of DHA on the inhibitor-
induced decrease in PLD activity in presence of the PLD1 only. Both AA and DHA
are reported to promote the PLD2-stimulating mediators ARF, PIP2, and Rac2, thus
abrogating the suppressing effect of the PLD2 inhibitor (FU et al. 1998; DIAZ et al.
2002; ARAKI et al. 2005; SELVY et al. 2011). In addition, AA contributes to the
activation of PLD1 regulating factors namely, ARF, Rho and PKCα (FU et al. 1998;
ARAKI et al. 2005), which leads to the inhibitory action of AA on the PLD2 inhibitor.
The divergent actions of DHA and AA in presence of the PLD2 inhibitor are of
particular significance with regard to the observation made by Gueck and his co-
workers that DHA inhibits, but AA promotes mast cell mediator release. With respect
to the data presented in this work it can be speculated that the two PLD isoforms are
DISCUSSION
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of varying impact for mast cell exocytosis processes with PLD1 being of prime
importance.
The above mentioned different effects of PUFA on PLD isoforms go along with the
results obtained by Gueck and his co-workers (GUECK et al. 2003; GUECK et al.
2004a; b) who documented an inhibitory role of DHA and a stimulatory effect of AA
on the release of mast cell mediators.
PLD1 has a central role in regulating degranulation in mast cells by enhancing
receptor-induced degranulation (SELVY et al. 2011). In the present study AA
suppresses the inhibitory effect of PLD2 inhibitor; increasing the PLD activity.
Therefore AA enhances the exocytosis process due to its stimulatory effect on the
activity of PLD1. In contrast, DHA did not induce further increase in PLD1 activity and
this is the result of its inhibitory effect on the exocytosis process.
5.7 Conclusion
PUFA of both the n-3 and the n-6 families are well integrated in raft as well as non-
raft membrane domains of C2 mast cells leading to a modification and reorganization
of the microdomains. This modification of lipid rafts has an impact on the localization
and activity of the PLD. The present work shows that a DHA supplementation of C2
mast cells abolishes the stimulation-induced translocation of PLD1 to the plasma
membrane and increases the total activity of the PLD, which might be due to an
effect on the PLD2 isoform. AA supplementation of C2 mast cells, in contrast, does
not prevent the translocation of PLD1 to the plasma membrane due to stimulation,
and increases the activity of both PLD isoforms.
The data gained provide a mechanistic explanation for the suppression of mast cell
release of pro-inflammatory mediators by LNA, EPA, DHA and LA in vivo (NESBITT
et al. 2003; GLOS et al. 2008) and in vitro (GUECK et al. 2003; GUECK et al. 2004a;
b). The inhibition of the stimulation-induced translocation of the PLD1 to the plasma
membrane, paves the way for a slowing-down of mast cell exocytosis. The
stimulatory action of DHA on the PLD2, however, seems to be negligible in context of
the mast cell mediator liberation. On the other hand, the increase in pro-inflammatory
mediators release by AA in vitro (GUECK et al. 2003; GUECK et al. 2004a; b) could
DISCUSSION
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be explained by the permission of the stimulation-induced migration of PLD1 to the
plasma membrane in combination with an enhancing effect on the activity of both the
PLD1 and the PLD2.
All together, this work helps to understand the physiology of canine mast cells under
the influence of dietary fatty acids. The data presented contribute to a better
comprehension of the secretory mechanisms of mast cells, and may initiate a more
directed way in the therapy of CAD using unsaturated fatty acids.
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Polyunsaturated fatty acids (PUFA) have been used with some success in the 
treatment of canine atopic dermatitis (CAD). Correspondent in vitro studies revealed 
that PUFA play a crucial role in the exocytosis of mast cells. n3 PUFA such as α-
linolenic acid (LNA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), as 
well as the n6 PUFA linoleic acid (LA) have been shown to arrest the secretion of 
inflammatory mediators. Contrary, the n-6 PUFA arachidonic acid (AA) has been 
proven to promote the production of mast cell inflammatory mediators. However, we 
are still lacking a complete picture of the mode of action. The goal of this work was to 
further characterize the modulatory effects of PUFA supplementation on the plasma 
membrane lipid composition of mast cells. Furthermore the consequences of a 
membrane modulation of mast cells by PUFA on the localization and activity on of the 
membrane bound enzyme phospholipases D (PLD) were investigated. 
Canine mastocytoma cells (C2) were supplemented with one of the following PUFA: 
LNA, EPA, DHA, LA or AA. To investigate the influence of PUFA on the lipid 
composition of membrane microdomains, lipid rafts were separated from non-raft 
plasma membranes of mast cells for the first time using a detergent-free isolation 
technique. Results show that PUFA are significantly increased in rafts as well as in 
non-rafts microdomains (Publication 1). The incorporation of PUFA into the 
membrane goes along with an increase of the unsaturation status and the fluidity of 
the membrane. This rise in membrane fluidity may result in a reorganization of 
membrane signaling molecules and enzymes such as the PLD.  
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To define the impact of a PUFA supplementation on PLD trafficking, C2 were 
transfected with green fluorescent protein (GFP) fusion plasmids encoding PLD1 or 
PLD2. Since the transfection ability of the suspension cell line C2 is limited, a special 
transfection protocol was established, suitable for non-adherent cell lines. 
Transfection succeeded using chicken egg white as coating material for the cell 
culture plates. The transfection efficiency rose to 50% versus 5% in uncoated plates. 
In addition to the obvious increase in the transfection efficiency, the new technique is 
simple and economic and might be suitable for a wide range of suspension cell lines 
(Publication 2). 
Using this optimized protocol the influence of PUFA on the trafficking of PLD isoforms 
was studied. LNA, EPA, DHA and LA but not AA prevented the stimulation-induced 
translocation of PLD1 to the plasma membrane. Since the translocation of PLD1 is 
important for mast cell exocytosis, LNA, EPA, DHA and LA do have an inhibiting 
effect on the stimulation-induced release of pro-inflammatory mediators. All PUFA 
tested boosted the total PLD activity. In order to rule out, which PLD isoform was 
affected by the PUFA, the mast cells were supplemented with DHA or AA in the 
presence of specific PLD isoform inhibitors. DHA completely abolished the inhibitiory 
effect of the PLD1 inhibitor but had no effect on the inhibitory effect of PLD2 inhibitor. 
On the other hand, AA suppressed the inhibitory effect of both PLD1 and PLD2 
inhibitor (Publication 3).  
Taking together, the studies provide a mechanistic base for the role of PUFA in the 
exocytosis processes of mast cells. PUFA of the n3 and the n6 families impact the 
lipid composition of membrane microdomains, which in turn lead to a modulation of 
the physiochemical properties of the membrane. LNA, EPA, DHA and LA suppress 
the release of inflammatory mediators through their inhibitory action on the 
stimulation-induced translocation of the PLD1. Contrariwise, AA permits the 
stimulation-induced migration of PLD1 to the plasma membrane and increases the 
activity of both PLD isoforms. Therefore, LNA, EPA, DHA and LA but not AA inhibit 
the release of mast cell inflammatory mediators upon stimulation. 
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Mehrfach ungesättigte Fettsäuren (PUFA) können mit einigem Erfolg zur Behandlung 
der caninen atopischen Dermatitis (CAD) eingesetzt werden. In vitro-Studien zeigten, 
dass PUFA eine entscheidende Rolle in der Exozytose von Mastzellen spielen. N-3-
PUFA wie α-Linolensäure (LNA), Eicosapentaensäure (EPA), Docosahexaensäure 
(DHA) sowie die n-6-PUFA Linolsäure (LA) können die Sekretion von 
Entzündungsmediatoren vermindern. Arachidonsäure (AA) als n-6 mehrfach 
ungesättigte Fettsäure hingegen fördert die Entzündungsmediatoren-Freisetzung aus 
den Mastzellen. Eine vollständige Aufklärung der Wirkungsweise fehlt aber weiterhin. 
Das Ziel dieser Arbeit war eine weitergehende Charakterisierung der modulierenden 
Effekte einer PUFA-Supplementierung auf die Lipidzusammensetzung der 
Plasmamembran von Mastzellen. Darüber hinaus wurden die Auswirkungen von 
PUFA auf die Lokalisation und Aktivität des Membran-gebundenen Enzyms 
Phospholipase D (PLD) untersucht.  
Canine Mastozytom-Zellen (C2) wurden mit einer der folgenden PUFA kultiviert: 
LNA, EPA, DHA, LA oder AA. Um den Einfluss von PUFA auf die 
Lipidzusammensetzung der Membran-Mikrodomänen zu untersuchen, konnten 
sowohl Lipid Raft als auch Nicht-Raft Plasmamembran-Anteile von Mastzellen zum 
ersten Mal mittels einer Detergenzien-freien Isolationsmethode getrennt werden. 
Hervorzuheben ist, dass PUFA signifikant vermehrt in Raft- sowie in Nicht-Raft 
Membranmikrodomänen eingelagert werden (Publikation 1). Die Integration von 
PUFA in die Membran geht mit einer Steigerung der Doppelbindungsanzahl und der 
Fluidität der Membran einher. Diese Erhöhung der Membranfluidität kann zu einer 
Reorganisation von membranären Signalmolekülen und Enzymen wie der PLD 
führen. 
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Um die Auswirkungen einer PUFA-Supplementierung auf den intrazellulären 
Transport der PLD in C2 zu bestimmen, wurden die Zellen mit PLD1- oder PLD2-
codierenden grün fluoreszierenden Protein-(GFP-)Fusionsplasmiden transfiziert. Da 
die Transfektionsfähigkeit der Suspensions-Zelllinie C2 begrenzt ist, wurde ein für 
nicht-adhärente Zelllinien geeignetes Transfektionsprotokoll etabliert. Mit 
Hühnereiweiß als Beschichtungsmaterial für die Zellkultur-Platten stieg die 
Transfektionseffizienz auf 50% im Vergleich zu 5% bei unbeschichteten Platten. 
Neben der deutlichen Erhöhung der Transfektionseffizienz ist die neu etablierte 
Technik einfach durchzuführen sowie wirtschaftlich und kann für eine Vielzahl von 
Suspension-Zelllinien geeignet sein (Publikation 2). 
Unter Verwendung dieses optimierten Protokolls wurde der Einfluss von PUFA auf 
die Translokation der PLD-Isoformen untersucht. LNA, EPA, DHA und LA, nicht aber 
AA verhindern die stimulationsinduzierte Translokation der PLD1 an die 
Plasmamembran. Die Translokation der PLD1 ist wichtig für die Mastzell-Exozytose. 
LNA, EPA, DHA und LA haben hier eine hemmende Wirkung auf die 
stimulationsinduzierte Freisetzung von proinflammatorischen Mediatoren. Alle 
getesteten PUFA verstärken die Gesamt-PLD-Aktivität. Um zu unterscheiden, welche 
PLD-Isoform durch PUFA beeinflusst ist, wurden die Mastzellen mit DHA oder AA in 
Gegenwart von PLD-Isoform-Inhibitoren supplementiert. DHA hebt die inhibitorische 
Wirkung des PLD1-Inhibitors vollständig auf, zeigte aber keinen Einfluss auf die 
hemmende Wirkung des PLD2-Inhibitors. Andererseits unterdrückt AA die 
hemmende Wirkung des PLD1- als auch des PLD2-Inhibitors (Publikation 3).  
Zusammenfassend bietet die Studie eine mechanistische Basis für die Rolle von 
PUFA bei Exozytose-Prozessen von Mastzellen. PUFA der n-3- und n-6-Familie 
beeinflussen die Lipidzusammensetzung von membranären Mikrodomänen, was 
wiederum zu einer Modulation der physikalisch-chemischen Eigenschaften der 
Membran führt. LNA, EPA, DHA und LA verhindern die Freisetzung von 
Entzündungsmediatoren durch ihre hemmende Wirkung auf die 
stimulationsinduzierte Translokation der PLD1. Umgekehrt erlaubt AA eine 
stimulationsinduzierte Migration der PLD1 zur Plasmamembran und steigert die 
Aktivität der beiden Isoformen der PLD. Somit hemmen LNA, EPA, DHA und LA, 
aber nicht AA die Freisetzung von Mastzell-Entzündungsmediatoren nach 
Stimulation. 
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